TY - JOUR
T1 - Vacuna tetravalente de influenza en los programas nacionales de inmunización para los países de América Latina
AU - Macías Hernández, Alejandro E.
AU - Santos, Fortino Solórzano
AU - Aguilar Velasco, Hugo M.
AU - Ávila Agüero, María L.
AU - Rubio, Fernando Bazzino
AU - Junqueira Bellei, Nancy C.
AU - Bonvehí, Pablo E.
AU - Del Castillo, José Brea
AU - Leguizamón, Héctor Castro
AU - Allan Santos Domingues, Carla M.
AU - García García, María D.L.
AU - Trujillo, Darío Londoño
AU - Lópe, Pío López
AU - De León Rosales, Samuel Ponce
AU - Cervantes Powell, Patricia G.
AU - Suárez Ognio, Luis A.N.
AU - Ruiz-Palacios y Santos, Guillermo M.
N1 - Publisher Copyright:
© 2020 Comunicaciones Cientificas Mexicanas S.A. de C.V.. All rights reserved.
PY - 2020/7
Y1 - 2020/7
N2 - Since 2012-2013 influenza season, World Health Organization (who) recommends the formulation of tetravalent vaccines. Globally, many countries already use tetravalent vaccines in their national immunization programs, while in Latin America only a small number. Two Influenza b lineages co-circulate, their epidemiological behavior is unpredictable. On average they represent 22.6% of influenza cases and more than 50% in predominant seasons. The lack of concordance between recommended and circulating strains was 25 and 32% in the 2010-2017 and 2000-2013 seasons, respectively. There are no clinical differences between influenza A and B. It occurs more frequently from five to 19 years of age. Influenza b has a higher proportion of attributable deaths than influenza a (1.1 vs. 0.4%), or 2.65 (95% ci 1.18-5.94). A greater number of hospitalizations when the strains mismatch (46.3 vs. 28.5%; p <.0001). Different evaluations have demonstrated its cost effectiveness. The compilation of this information supports the use of quadrivalent vaccines in Latin American countries.
AB - Since 2012-2013 influenza season, World Health Organization (who) recommends the formulation of tetravalent vaccines. Globally, many countries already use tetravalent vaccines in their national immunization programs, while in Latin America only a small number. Two Influenza b lineages co-circulate, their epidemiological behavior is unpredictable. On average they represent 22.6% of influenza cases and more than 50% in predominant seasons. The lack of concordance between recommended and circulating strains was 25 and 32% in the 2010-2017 and 2000-2013 seasons, respectively. There are no clinical differences between influenza A and B. It occurs more frequently from five to 19 years of age. Influenza b has a higher proportion of attributable deaths than influenza a (1.1 vs. 0.4%), or 2.65 (95% ci 1.18-5.94). A greater number of hospitalizations when the strains mismatch (46.3 vs. 28.5%; p <.0001). Different evaluations have demonstrated its cost effectiveness. The compilation of this information supports the use of quadrivalent vaccines in Latin American countries.
KW - Influenza b
KW - Latin America
KW - Tetravalent influenza vaccine
UR - https://www.scopus.com/pages/publications/85096872537
M3 - Artículo
AN - SCOPUS:85096872537
SN - 1405-0994
VL - 40
SP - 92
EP - 99
JO - Enfermedades Infecciosas y Microbiologia
JF - Enfermedades Infecciosas y Microbiologia
IS - 3
ER -
